Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049919 | 0.81 | NR1H4 (0.52) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL8081516 | 0.78 | TP53 (0.47) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL3059737 | 0.77 | MTNR1A (0.44) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL2020434 | 0.74 | MTNR1A (0.59) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL12450012 | 0.73 | MTNR1A (0.57) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL1395799 | 0.72 | HTR2A (0.52) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL2024854 | 0.72 | MTNR1A (0.56) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL3054307 | 0.70 | HTR2A (0.50) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL3054218 | 0.70 | HTT (0.49) | MTNR1AMTNR1B | |
| SCHEMBL1395803 | 0.70 | MTNR1A (0.54) | MTNR1AMTNR1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | MTNR1A 2791/4885MTNR1B 3211/4885KCNQ2 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.